LRRK2 and Crohn disease: Since the N2081D LRRK2 mutation confers risk for PD as well as for Crohn's disease (Hui et al., 2018), further studies are warranted to probe for centrosomal deficits in peripheral cells from Crohn's disease patients, as this may aid in stratifying patients benefitting from LRRK2 kinase inhibitor therapeutics in clinical studies.